166411-96-7

Basic information

• Product Name: 3-METHOXY-6,6A-DIHYDRO-1AH-1-OXA-CYCLOPROPA[A]INDENE
• Synonyms: 3-METHOXY-6,6A-DIHYDRO-1AH-1-OXA-CYCLOPROPA[A]INDENE
• CAS NO: 166411-96-7
• Molecular Formula: C10H10O2
• Molecular Weight: 162.1852
• Mol File: 166411-96-7.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-METHOXY-6,6A-DIHYDRO-1AH-1-OXA-CYCLOPROPA[A]INDENE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-METHOXY-6,6A-DIHYDRO-1AH-1-OXA-CYCLOPROPA[A]INDENE(166411-96-7)
• EPA Substance Registry System: 3-METHOXY-6,6A-DIHYDRO-1AH-1-OXA-CYCLOPROPA[A]INDENE(166411-96-7)

Safety Data

• Hazardous Substances Data: 166411-96-7(Hazardous Substances Data)

Usage

Molecular structure

Cyclic compound containing a cyclopropa[a]indene ring system

Functional group

Methoxy group (CH3O-) attached to the 3-carbon position

Potential applications

Organic synthesis, pharmaceutical research

Uses

Building block in the development of drugs or materials

Importance

Interesting structural features, potential biological activities

Future prospects

Valuable discoveries and applications through further studies and investigations

Upstream product

• 3469-07-6 5-methoxy-1H-indene 
• 3469-09-8 6-methoxyindan-1-ol 
• 13623-25-1 6-methoxy-2,3-dihydro-1H-inden-1-one 
• 1929-29-9 3-(4-methoxyphenyl)propanoic acid 
• 91789-12-7 trans-2-bromo-6-methoxyindan-1-ol 

Relevant articles and documents

DERIVATIVES OF AMINOINDANES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS

The instant invention relates to derivatives of formula (I) and their application in therapeutics.

Synthesis of chiral building blocks for use in drug discovery

In the past decade there has been a significant growth in the sales of pharmaceutical drugs worldwide, but more importantly there has been a dramatic growth in the sales of single enantiomer drugs. The pharmaceutical industry has a rising demand for chiral intermediates and research reagents because of the continuing imperative to improve drug efficacy. This in turn impacts on researchers involved in preclinical discovery work. Besides traditional chiral pool and resolution of racemates as sources of chiral building blocks, many new synthetic methods including a great variety of catalytic reactions have been developed which facilitate the production of complex chiral drug candidates for clinical trials. The most ambitious technique is to synthesise homochiral compounds from non-chiral starting materials using chiral metal catalysts and related chemistry. Examples of the synthesis of chiral building blocks from achiral materials utilizing asymmetric hydrogenation and asymmetric epoxidation are presented.